What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective
Standard
What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective. / Spadaccini, Marco; Canziani, Lorenzo; Aghemo, Alessio; Lleo, Ana; Maselli, Roberta; Anderloni, Andrea; Carrara, Silvia; Fugazza, Alessandro; Pellegatta, Gaia; Galtieri, Piera Alessia; Hassan, Cesare; Greenwald, David; Pochapin, Mark; Wallace, Michael; Sharma, Prateek; Roesch, Thomas; Bhandari, Pradeep; Emura, Fabian; Raju, Gottumukkala S; Repici, Alessandro; World Endoscopy Organization COVID-19 Committee.
in: UNITED EUR GASTROENT, Jahrgang 9, Nr. 7, 09.2021, S. 787-796.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective
AU - Spadaccini, Marco
AU - Canziani, Lorenzo
AU - Aghemo, Alessio
AU - Lleo, Ana
AU - Maselli, Roberta
AU - Anderloni, Andrea
AU - Carrara, Silvia
AU - Fugazza, Alessandro
AU - Pellegatta, Gaia
AU - Galtieri, Piera Alessia
AU - Hassan, Cesare
AU - Greenwald, David
AU - Pochapin, Mark
AU - Wallace, Michael
AU - Sharma, Prateek
AU - Roesch, Thomas
AU - Bhandari, Pradeep
AU - Emura, Fabian
AU - Raju, Gottumukkala S
AU - Repici, Alessandro
AU - World Endoscopy Organization COVID-19 Committee
N1 - © 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.
PY - 2021/9
Y1 - 2021/9
N2 - BACKGROUND: The novel Coronavirus (SARS-CoV-2) has caused almost 2 million deaths worldwide. Both Food and Drug Administration and European Medicines Agency have recently approved the first COVID-19 vaccines, and a few more are going to be approved soon.METHODS: Several different approaches have been used to stimulate the immune system in mounting a humoral response. As more traditional approaches are under investigation (inactivated virus vaccines, protein subunit vaccines, recombinant virus vaccines), more recent and innovative strategies have been tried (non-replicating viral vector vaccines, RNA based vaccines, DNA based vaccines).RESULTS: Since vaccinations campaigns started in December 2020 in both the US and Europe, gastroenterologists will be one of the main sources of information regarding SARS-CoV 2 vaccination for patients in their practice, including vulnerable patients such as those with Inflammatory Bowel Disease (IBD), patients with chronic liver disease, and GI cancer patients.CONCLUSIONS: Thus, we must ourselves be well educated and updated in order to provide unambiguous counseling to these categories of vulnerable patients. In this commentary, we aim to provide a comprehensive review of both approved COVID-19 vaccines and the ones still under development, and explore potential risks, benefits and prioritization of vaccination.
AB - BACKGROUND: The novel Coronavirus (SARS-CoV-2) has caused almost 2 million deaths worldwide. Both Food and Drug Administration and European Medicines Agency have recently approved the first COVID-19 vaccines, and a few more are going to be approved soon.METHODS: Several different approaches have been used to stimulate the immune system in mounting a humoral response. As more traditional approaches are under investigation (inactivated virus vaccines, protein subunit vaccines, recombinant virus vaccines), more recent and innovative strategies have been tried (non-replicating viral vector vaccines, RNA based vaccines, DNA based vaccines).RESULTS: Since vaccinations campaigns started in December 2020 in both the US and Europe, gastroenterologists will be one of the main sources of information regarding SARS-CoV 2 vaccination for patients in their practice, including vulnerable patients such as those with Inflammatory Bowel Disease (IBD), patients with chronic liver disease, and GI cancer patients.CONCLUSIONS: Thus, we must ourselves be well educated and updated in order to provide unambiguous counseling to these categories of vulnerable patients. In this commentary, we aim to provide a comprehensive review of both approved COVID-19 vaccines and the ones still under development, and explore potential risks, benefits and prioritization of vaccination.
KW - 2019-nCoV Vaccine mRNA-1273
KW - Ad26COVS1/therapeutic use
KW - BNT162 Vaccine/therapeutic use
KW - COVID-19/prevention & control
KW - COVID-19 Vaccines/therapeutic use
KW - ChAdOx1 nCoV-19/therapeutic use
KW - Gastroenterology
KW - Gastrointestinal Neoplasms/therapy
KW - Humans
KW - Inflammatory Bowel Diseases/therapy
KW - Liver Diseases/therapy
KW - SARS-CoV-2
U2 - 10.1002/ueg2.12103
DO - 10.1002/ueg2.12103
M3 - SCORING: Review article
C2 - 34102015
VL - 9
SP - 787
EP - 796
JO - UNITED EUR GASTROENT
JF - UNITED EUR GASTROENT
SN - 2050-6406
IS - 7
ER -
